Sarah Cannon Research Institute University of Oklahoma

Clinical research site in Oklahoma City, Oklahoma

Part of Sarah Cannon Research Institute

As of July 2026, 2 paid clinical trials are recruiting at Sarah Cannon Research Institute University of Oklahoma in Oklahoma City, Oklahoma. Active studies at this site cover conditions such as Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) and Neuroendocrine Prostate Cancer (NEPC). Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Sarah Cannon Research Institute University of Oklahoma (2)

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

for Small Cell Lung Cancer (SCLC)

15 locations incl. Duarte

Sponsor: Phanes Therapeutics

Sex: All·Age: 18+

Code: NCT05652686·Phase 1, Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

for Non Small Cell Lung Cancer

5 locations incl. Huntersville

Sponsor: Phanes Therapeutics

Sex: All·Age: 18+

Code: NCT05431270·Phase 1, Phase 2·Recruiting·Listed Jun 2022

Apply to this trial

More research sites in Oklahoma City

University of Oklahoma Health Sciences Center (183 trials)
Mercy Hospital Oklahoma City (50 trials)
University of Oklahoma (26 trials)
OU Health Stephenson Cancer Center (19 trials)
Stephenson Cancer Center (14 trials)
Oklahoma Medical Research Foundation (11 trials)
The University of Oklahoma Health Sciences Center (11 trials)
Hightower Clinical (10 trials)
Oklahoma Heart Hospital (8 trials)
TSET Health Promotion Research Center (8 trials)

Explore more

Paid clinical trials in Oklahoma City, OK · Oklahoma clinical trials